
RenovoRx (RNXT) Stock Forecast & Price Target
RenovoRx (RNXT) Analyst Ratings
Bulls say
RenovoRx is a clinical-stage biopharmaceutical company with a promising lead drug candidate and a strong financial position, with $12 million in cash and no debt. The company's recent milestones include a new CFO appointment, positive results from interim analyses of their ongoing Phase III TIGeR-PaC trial, and strong revenue growth for its commercial product RenovoCath. Based on these positive developments and the potential for a billion dollar market, the analyst believes there is significant upside potential for RenovoRx's stock.
Bears say
RenovoRx is a clinical-stage biopharmaceutical company that has a negative outlook, as their particular drug delivery platform has faced slow growth due to a long induction phase and a high percentage of ineligible patients for randomization. Additionally, the company's valuation is not attractive, and they have reported losses on issuances of financial instruments. It is important to note that while RenovoRx has made progress in clinical development and commercialization, it may not be enough to offset the challenges faced by their current approach.
This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.
RenovoRx (RNXT) Analyst Forecast & Price Prediction
Start investing in RenovoRx (RNXT)
Order type
Buy in
Order amount
Est. shares
0 shares